A Presenilin 1 Mutation Associated with Familial Frontotemporal Dementia Inhibits γ-Secretase Cleavage of APP and Notch

A novel presenilin 1 mutation, insR352, associated with a frontal temporal dementia phenotype has been identified (E. A. Rogaeva et al., 2001, Neurology 57, 621-625). This mutation does not increase Abeta42 levels, but instead acts as dominant negative presenilin, decreasing amyloid beta protein (Abeta) production by inhibiting gamma-secretase cleavage of the Abeta precursor. The distinct clinical phenotype associated with this mutation suggests that chronic partial inhibition of gamma-secretase activity may result in neurodegeneration.

[1]  R. Petersen,et al.  Familial Frontotemporal Dementia Associated with a Novel Presenilin-1 Mutation , 2002, Dementia and Geriatric Cognitive Disorders.

[2]  You-Qiang Song,et al.  Screening for PS1 mutations in a referral-based series of AD cases , 2001, Neurology.

[3]  S. Younkin,et al.  Presenilins as therapeutic targets for the treatment of Alzheimer's disease. , 2001, Trends in molecular medicine.

[4]  D. Campion,et al.  Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation , 2000, Neurology.

[5]  Robert A. Copeland,et al.  Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors* , 2000, The Journal of Biological Chemistry.

[6]  P. Fraser,et al.  Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage. , 2000, The Journal of biological chemistry.

[7]  T. Golde,et al.  γ-Secretase, Evidence for Multiple Proteolytic Activities and Influence of Membrane Positioning of Substrate on Generation of Amyloid β Peptides of Varying Length* , 1999, The Journal of Biological Chemistry.

[8]  D. Selkoe,et al.  Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity , 1999, Nature.

[9]  Raphael Kopan,et al.  Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain , 1998, Nature.

[10]  J. Hardy,et al.  Increased Aβ42(43) from cell lines expressing presenilin 1 mutations , 1998, Annals of neurology.

[11]  John Hardy,et al.  Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.

[12]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[13]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[14]  Brian J Cummings,et al.  Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[15]  L. Villa-komaroff,et al.  Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.